Literature DB >> 16302086

Laser for the treatment of twin to twin transfusion syndrome.

Denise Araújo Lapa Pedreira1, Gregório Lorenzo Acácio, Carolina Leite Drummond, Rita de Cássia Sanchez e Oliveira, Alice D'Agostini Deustch, Wladimir Guimarães Taborda.   

Abstract

PURPOSE: To report the initial experience in our country with a new technique for twin to twin transfusion syndrome (TTTS) treatment, using laser to coagulate the placental vessels responsible for the twin transfusion during gestation.
METHODS: Prospective study of eight cases diagnosed with TTTS evaluated in our service from january 2001 to june 2005. Through percutaneous introduction of a 2,0mm diameter fetoscope in the uterine cavity, placental surface vessels where directly visualized. Those identified as responsible for the transfusion were laser coagulated. The procedure combines ultrasonography and fetoscopy, in a so-called sonoendoscopic technique (FETENDO).
RESULTS: Among the eight pregnancies evaluated, five cases were submitted to the procedure (10 fetuses). All fetuses survived for at least five weeks after surgery. A total of eight fetuses were born alive and five survived the neonatal period. In a 18 months follow-up after birth, all five are still alive and well and their mean age is now 10,6 months. The total survival rate was 50% and in three pregnancies, at least one fetus survived.
CONCLUSIONS: Laser fetoscopy is actually the "gold-standard" treatment of TTTS. Nevertheless is a sophisticated technique that depends of proper training. Our service is the first in our country to offer this therapeutic technique. Our success rate is comparable with the international literature.

Entities:  

Mesh:

Year:  2005        PMID: 16302086     DOI: 10.1590/s0102-86502005000600015

Source DB:  PubMed          Journal:  Acta Cir Bras        ISSN: 0102-8650            Impact factor:   1.388


  1 in total

1.  A novel ultrasmall composite optical fiberscope.

Authors:  Kiyoshi Oka; Takeshi Seki; Akihiro Naganawa; Keri Kim; Toshio Chiba
Journal:  Surg Endosc       Date:  2011-02-07       Impact factor: 4.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.